Cristina Gutierrez1, Colleen McEvoy2, Laveena Munshi3, R Scott Stephens4, Michael E Detsky5, Joseph L Nates6, Stephen M Pastores7,8. 1. Department of Critical Care, The University of Texas M.D. Anderson Cancer Center, Houston, TX. 2. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, MO. 3. Interdepartmental Division of Critical Care Medicine, Toronto General Hospital, Toronto, ON, Canada. 4. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University, Baltimore, MD. 5. Interdepartmental Division of Critical Care Medicine, Mount Sinai Hospital, Toronto, ON, Canada. 6. Division of Anesthesiology and Critical Care, Department of Critical Care, The University of Texas M.D. Anderson Cancer Center, Houston, TX. 7. Department of Anesthesiology and Critical Care Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. 8. Departments of Medicine and Anesthesiology and Critical Care Medicine, Weill Cornell Medical College, New York, NY.
Abstract
OBJECTIVES: To describe the most common serious adverse effects and organ toxicities associated with emerging therapies for cancer that may necessitate admission to the ICU. DATA SOURCES AND STUDY SELECTION: PubMed and Medline search of relevant articles in English on the management of adverse effects of immunotherapy for cancer. DATA EXTRACTION AND DATA SYNTHESIS: Targeted therapies including tyrosine kinase inhibitors, monoclonal antibodies, checkpoint inhibitors, and immune effector cell therapy have improved the outcome and quality of life of patients with cancer. However, severe and life-threatening side effects can occur. These toxicities include infusion or hypersensitivity reactions, cytokine release syndrome, pulmonary, cardiac, renal, hepatic, and neurologic toxicities, hemophagocytic lymphohistiocytosis, opportunistic infections, and endocrinopathies. Cytokine release syndrome is the most common serious toxicity after administration of monoclonal antibodies and immune effector cell therapies. Most of the adverse events from immunotherapy results from an exaggerated T-cell response directed against normal tissue, resulting in the generation of high levels of proinflammatory cytokines. Toxicities from targeted therapies are usually secondary to "on target toxicities." Management is largely supportive and may include discontinuation of the specific agent, corticosteroids, and other immune suppressing agents for severe (grade 3 or 4) immune-related adverse events like neurotoxicity and pneumonitis. CONCLUSIONS: The complexity of toxicities associated with modern targeted and immunotherapeutic agents for cancer require a multidisciplinary approach among ICU staff, oncologists, and organ specialists and adoption of standardized treatment protocols to ensure the best possible patient outcomes.
OBJECTIVES: To describe the most common serious adverse effects and organ toxicities associated with emerging therapies for cancer that may necessitate admission to the ICU. DATA SOURCES AND STUDY SELECTION: PubMed and Medline search of relevant articles in English on the management of adverse effects of immunotherapy for cancer. DATA EXTRACTION AND DATA SYNTHESIS: Targeted therapies including tyrosine kinase inhibitors, monoclonal antibodies, checkpoint inhibitors, and immune effector cell therapy have improved the outcome and quality of life of patients with cancer. However, severe and life-threatening side effects can occur. These toxicities include infusion or hypersensitivity reactions, cytokine release syndrome, pulmonary, cardiac, renal, hepatic, and neurologic toxicities, hemophagocytic lymphohistiocytosis, opportunistic infections, and endocrinopathies. Cytokine release syndrome is the most common serious toxicity after administration of monoclonal antibodies and immune effector cell therapies. Most of the adverse events from immunotherapy results from an exaggerated T-cell response directed against normal tissue, resulting in the generation of high levels of proinflammatory cytokines. Toxicities from targeted therapies are usually secondary to "on target toxicities." Management is largely supportive and may include discontinuation of the specific agent, corticosteroids, and other immune suppressing agents for severe (grade 3 or 4) immune-related adverse events like neurotoxicity and pneumonitis. CONCLUSIONS: The complexity of toxicities associated with modern targeted and immunotherapeutic agents for cancer require a multidisciplinary approach among ICU staff, oncologists, and organ specialists and adoption of standardized treatment protocols to ensure the best possible patient outcomes.
Authors: Sattva S Neelapu; Sudhakar Tummala; Partow Kebriaei; William Wierda; Cristina Gutierrez; Frederick L Locke; Krishna V Komanduri; Yi Lin; Nitin Jain; Naval Daver; Jason Westin; Alison M Gulbis; Monica E Loghin; John F de Groot; Sherry Adkins; Suzanne E Davis; Katayoun Rezvani; Patrick Hwu; Elizabeth J Shpall Journal: Nat Rev Clin Oncol Date: 2017-09-19 Impact factor: 66.675
Authors: Syed S Mahmood; Michael G Fradley; Justine V Cohen; Anju Nohria; Kerry L Reynolds; Lucie M Heinzerling; Ryan J Sullivan; Rongras Damrongwatanasuk; Carol L Chen; Dipti Gupta; Michael C Kirchberger; Magid Awadalla; Malek Z O Hassan; Javid J Moslehi; Sachin P Shah; Sarju Ganatra; Paaladinesh Thavendiranathan; Donald P Lawrence; John D Groarke; Tomas G Neilan Journal: J Am Coll Cardiol Date: 2018-03-19 Impact factor: 24.094
Authors: Winnie Yeo; Tung C Chan; Nancy W Y Leung; Wai Y Lam; Frankie K F Mo; Miu Ting Chu; Henry L Y Chan; Edwin P Hui; Kenny I K Lei; Tony S K Mok; Paul K S Chan Journal: J Clin Oncol Date: 2008-12-15 Impact factor: 44.544
Authors: Chrisann Kyi; Matthew D Hellmann; Jedd D Wolchok; Paul B Chapman; Michael A Postow Journal: J Immunother Cancer Date: 2014-06-18 Impact factor: 13.751
Authors: Marisol Maldonado; Colleen E Villamin; Leah E Murphy; Amitava Dasgupta; Roland L Bassett; Mayrin Correa Medina; Tonita S Bates; Fernando Martinez; Adriana M Knopfelmacher Couchonal; Kimberly Klein; James M Kelley Journal: Lab Med Date: 2022-07-04
Authors: Fernando G Zampieri; Thiago G Romano; Jorge I F Salluh; Leandro U Taniguchi; Pedro V Mendes; Antonio P Nassar; Roberto Costa; William N Viana; Marcelo O Maia; Mariza F A Lima; Sylas B Cappi; Alexandre G R Carvalho; Fernando V C De Marco; Marcelo S Santino; Eric Perecmanis; Fabio G Miranda; Grazielle V Ramos; Aline R Silva; Paulo M Hoff; Fernando A Bozza; Marcio Soares Journal: Intensive Care Med Date: 2020-08-07 Impact factor: 17.440
Authors: Dristhi Ragoonanan; Sajad J Khazal; Hisham Abdel-Azim; David McCall; Branko Cuglievan; Francesco Paolo Tambaro; Ali Haider Ahmad; Courtney M Rowan; Cristina Gutierrez; Keri Schadler; Shulin Li; Matteo Di Nardo; Linda Chi; Alison M Gulbis; Basirat Shoberu; Maria E Mireles; Jennifer McArthur; Neena Kapoor; Jeffrey Miller; Julie C Fitzgerald; Priti Tewari; Demetrios Petropoulos; Jonathan B Gill; Christine N Duncan; Leslie E Lehmann; Sangeeta Hingorani; Joseph R Angelo; Rita D Swinford; Marie E Steiner; Fiorela N Hernandez Tejada; Paul L Martin; Jeffery Auletta; Sung Won Choi; Rajinder Bajwa; Natalie Dailey Garnes; Partow Kebriaei; Katayoun Rezvani; William G Wierda; Sattva S Neelapu; Elizabeth J Shpall; Selim Corbacioglu; Kris M Mahadeo Journal: Nat Rev Clin Oncol Date: 2021-02-19 Impact factor: 65.011
Authors: Robert S Ackerman; Aaron R Muncey; Nasrin N Aldawoodi; Rohini Kotha; Rosemarie E Garcia Getting Journal: Curr Oncol Rep Date: 2022-02-10 Impact factor: 5.945
Authors: Anna S Messmer; Yok-Ai Que; Christoph Schankin; Yara Banz; Ulrike Bacher; Urban Novak; Thomas Pabst Journal: Wien Klin Wochenschr Date: 2021-10-06 Impact factor: 1.704
Authors: Courtney Andrews; Timothy C Childers; Kimberly D Wiseman; Valerie Lawhon; Stacey Ingram; Mary Lou Smith; Antonio C Wolff; Lynne Wagner; Gabrielle B Rocque Journal: BMC Cancer Date: 2022-02-04 Impact factor: 4.430